Physician profile
William S Donnell
NPI 1639191125
$1,864.69
in general payments reported to CMS, 2019-2025
28 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $25.98 · 2021: $76.96 · 2022: $322 · 2023: $506 · 2024: $418 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,060.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $213.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $201.15 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Astrazeneca Pharmaceuticals LP | $200.13 | 2019-2025 | Airsupra, Breztri |
| Abbvie INC. | $139.48 | 2021-2025 | Vraylar |
| Glaxosmithkline, LLC. | $123.77 | 2019-2024 | Arexvy, Shingrix |
| Abbott Laboratories | $116.07 | 2022-2025 | Freestyle Libre |
| Biohaven Pharmaceutical Holding Company LTD. | $107.29 | 2022 | |
| Merck Sharp & Dohme LLC | $98.64 | 2019-2024 | Gardasil, Gardasil 9, Vaxelis |
| Eisai INC. | $88.80 | 2024-2025 | |
| Pfizer INC. | $87.03 | 2019-2024 | |
| Amgen INC. | $74.12 | 2019-2025 | Evenity, Prolia, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $43.63 | 2019 | |
| Idorsia Pharmaceuticals US INC | $38.49 | 2022-2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $38.34 | 2023-2024 | Gvoke Hypopen |
| Avanir Pharmaceuticals, INC. | $32.55 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $28.93 | 2022-2023 | |
| Mylan Specialty L.P. | $27.79 | 2019-2023 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.73 | 2023 | Xifaxan |
| Dexcom, INC. | $26.92 | 2022-2023 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $25.55 | 2019-2024 | Austedo Xr |
| Exact Sciences Corporation | $20.95 | 2024 | Cologuard Collection Kit |
| Sobi, INC | $17.66 | 2022 | |
| Astellas Pharma US INC | $17.11 | 2019 | |
| Ironwood Pharmaceuticals, INC | $15.22 | 2024 | |
| Janssen Pharmaceuticals, INC | $15.20 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.11 | 2019 | |
| Horizon Therapeutics Plc | $12.72 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Donnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.